CJH Stock Chart & Stats
€4.74
-€0.04(-1.16%)
At close: 4:00 PM EST
€4.74
-€0.04(-1.16%)
Day’s Range― - ―
52-Week Range€2.28 - €5.70
Previous CloseN/A
Volume0.00
Average Volume (3M)73.00
Market Cap
€1.36B
Enterprise Value€4.51K
Total Cash (Recent Filing)€1.84B
Total Debt (Recent Filing)€979.87M
Price to Earnings (P/E)347.0
Beta1.12
Next Earnings
Nov 02, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding132,670,900
10 Day Avg. Volume20
30 Day Avg. Volume73
Financial Highlights & Ratios
PEG Ratio-2.66
Price to Book (P/B)1.60
Price to Sales (P/S)7.70
P/FCF Ratio-52.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.61Price Target Upside18.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.04
Revenue Forecast (FY)€158.36M
Bulls Say, Bears Say
Bulls Say
End-to-end Vaccine PlatformCanSino’s integrated vaccine model spans research, development, regulatory submissions, manufacturing, and commercialization. This broad capability can support control over product execution, enable multiple vaccine platforms, and create durable opportunities across domestic and international markets.
Revenue And Gross-margin ImprovementRecent revenue growth alongside a strong gross margin indicates improving commercial traction and meaningful product economics. If maintained, this combination can provide more resources for research, regulatory work, and production while supporting progress toward sustainable profitability.
Moderate LeverageModerate leverage and a sizable equity base give CanSino a comparatively supportive financial foundation for a biotechnology company. Lower debt dependence can preserve flexibility to fund vaccine development and absorb earnings volatility while the business works toward consistent returns.
Bears Say
Persistent Negative Free Cash FlowMeaningfully negative free cash flow shows that investment spending still exceeds internally generated cash. Continued cash burn can reduce financial flexibility and leave CanSino dependent on maintaining liquidity or accessing financing until commercial scale produces sustainably positive free cash flow.
Profitability Remains FragileThe company has not yet demonstrated durable operating profitability despite revenue growth and strong gross margins. Slightly negative operating income and near-breakeven net results limit internally funded expansion and make future earnings more sensitive to changes in vaccine sales and spending.
High Earnings Volatility And Low ReturnsLarge swings from profit to heavy losses, together with low TTM return on equity, indicate that CanSino’s capital base is not yet producing consistent returns. This weakens confidence in earnings quality and suggests that growth has not fully translated into dependable shareholder profitability.
CanSino Biologics, Inc. Class H News
CJH FAQ
What was CanSino Biologics, Inc. Class H’s price range in the past 12 months?
CanSino Biologics, Inc. Class H lowest stock price was €2.28 and its highest was €5.70 in the past 12 months.
What is CanSino Biologics, Inc. Class H’s market cap?
CanSino Biologics, Inc. Class H’s market cap is €1.36B.
When is CanSino Biologics, Inc. Class H’s upcoming earnings report date?
CanSino Biologics, Inc. Class H’s upcoming earnings report date is Nov 02, 2026 which is in 44 days.
How were CanSino Biologics, Inc. Class H’s earnings last quarter?
CanSino Biologics, Inc. Class H released its earnings results on Aug 27, 2026. The company reported €0.021 earnings per share for the quarter, missing the consensus estimate of €0.026 by -€0.006.
Is CanSino Biologics, Inc. Class H overvalued?
According to Wall Street analysts CanSino Biologics, Inc. Class H’s price is currently Undervalued.
Does CanSino Biologics, Inc. Class H pay dividends?
CanSino Biologics, Inc. Class H does not currently pay dividends.
What is CanSino Biologics, Inc. Class H’s EPS estimate?
CanSino Biologics, Inc. Class H’s EPS estimate is 0.03.
How many shares outstanding does CanSino Biologics, Inc. Class H have?
CanSino Biologics, Inc. Class H has 132,670,900 shares outstanding.
What happened to CanSino Biologics, Inc. Class H’s price movement after its last earnings report?
CanSino Biologics, Inc. Class H reported an EPS of €0.021 in its last earnings report, missing expectations of €0.026. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CanSino Biologics, Inc. Class H?
Currently, no hedge funds are holding shares in DE:CJH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CanSino Biologics, Inc. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€5.61 (18.31% Upside)
€5.61 (18.31% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.47%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CanSino Biologics, Inc. Class H
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.
CJH Stock 12 Month Forecast
Average Price Target
€5.61
▲(18.31% Upside)
Technical Analysis
HUTCHMED (China)
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Ab&B Bio-Tech CO., LTD. JS Class H
―
Xuanzhu Biopharmaceutical Co., Ltd. Class H
―